Progressive familial intrahepatic cholestasis

(Redirected from Byler Disease)
Jump to navigation Jump to search

WikiDoc Resources for Progressive familial intrahepatic cholestasis

Articles

Most recent articles on Progressive familial intrahepatic cholestasis

Most cited articles on Progressive familial intrahepatic cholestasis

Review articles on Progressive familial intrahepatic cholestasis

Articles on Progressive familial intrahepatic cholestasis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Progressive familial intrahepatic cholestasis

Images of Progressive familial intrahepatic cholestasis

Photos of Progressive familial intrahepatic cholestasis

Podcasts & MP3s on Progressive familial intrahepatic cholestasis

Videos on Progressive familial intrahepatic cholestasis

Evidence Based Medicine

Cochrane Collaboration on Progressive familial intrahepatic cholestasis

Bandolier on Progressive familial intrahepatic cholestasis

TRIP on Progressive familial intrahepatic cholestasis

Clinical Trials

Ongoing Trials on Progressive familial intrahepatic cholestasis at Clinical Trials.gov

Trial results on Progressive familial intrahepatic cholestasis

Clinical Trials on Progressive familial intrahepatic cholestasis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Progressive familial intrahepatic cholestasis

NICE Guidance on Progressive familial intrahepatic cholestasis

NHS PRODIGY Guidance

FDA on Progressive familial intrahepatic cholestasis

CDC on Progressive familial intrahepatic cholestasis

Books

Books on Progressive familial intrahepatic cholestasis

News

Progressive familial intrahepatic cholestasis in the news

Be alerted to news on Progressive familial intrahepatic cholestasis

News trends on Progressive familial intrahepatic cholestasis

Commentary

Blogs on Progressive familial intrahepatic cholestasis

Definitions

Definitions of Progressive familial intrahepatic cholestasis

Patient Resources / Community

Patient resources on Progressive familial intrahepatic cholestasis

Discussion groups on Progressive familial intrahepatic cholestasis

Patient Handouts on Progressive familial intrahepatic cholestasis

Directions to Hospitals Treating Progressive familial intrahepatic cholestasis

Risk calculators and risk factors for Progressive familial intrahepatic cholestasis

Healthcare Provider Resources

Symptoms of Progressive familial intrahepatic cholestasis

Causes & Risk Factors for Progressive familial intrahepatic cholestasis

Diagnostic studies for Progressive familial intrahepatic cholestasis

Treatment of Progressive familial intrahepatic cholestasis

Continuing Medical Education (CME)

CME Programs on Progressive familial intrahepatic cholestasis

International

Progressive familial intrahepatic cholestasis en Espanol

Progressive familial intrahepatic cholestasis en Francais

Business

Progressive familial intrahepatic cholestasis in the Marketplace

Patents on Progressive familial intrahepatic cholestasis

Experimental / Informatics

List of terms related to Progressive familial intrahepatic cholestasis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Prashanth Saddala M.B.B.S

Synonyms and keywords: Byler's disease, Greenland-Eskimo familial cholestasis

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Progressive familial intrahepatic cholestasis (PFIC) refers to a group of familial cholestatic conditions caused by defects in biliary epithelial transporters. The clinical presentation usually occurs first in childhood with progressive cholestasis. This usually leads to failure to thrive, hepatic failure, and the need for liver transplantation.

Historical Perspective

Classification

Pathophysiology

PFIC-1 is caused by a variety of mutations in ATP8B1, a gene coding for a P-type ATPase protein, FIC-1, that is responsible for phospholipid translocation.[1] It was previously identified as clinical entities known as Byler's disease and Greenland-Eskimo familial cholestasis. Patients with PFIC-1 may also have watery diarrhea, in addition to the clinical features below, due to FIC-1's expression in the intestine. How ATP8B1 mutation leads to cholestasis is not yet well understood.

PFIC-2 is caused by a variety of mutations in ABCB11, the gene that codes for the bile salt export pump, or BSEP. Retention of bile salts within hepatocytes, which are the only cell type to express BSEP, causes hepatocellular damage and cholestasis.

Progressive familial intrahepatic cholestasis is inherited in an autosomal recessive pattern.

PFIC-3 is caused by a variety of mutations in ABCB4, the gene encoding multidrug resistance protein 3 (MDR3),[2] which codes for a flippase responsible for phosphatidylcholine translocation. The defective phosphatidylcholine translocation leads to a lack of phosphatidylcholine in bile. Phosphatidylcholine normally chaperones bile acids, preventing damage to the biliary epithelium. The free or "unchaperoned" bile acids in bile of patients with MDR3 deficiency cause a cholangitis. Biochemically, this is of note, as PFIC-3 is associated with a markedly elevated GGT.

The inheritance pattern of all three forms of PFIC defined to date is autosomal recessive.

Similar transport protein mutations are believed to pose a higher risk for intrahepatic cholestasis of pregnancy.

Causes

Differentiating Progressive familial intrahepatic cholestasis from Other Diseases

Epidemiology and Demographics

Risk Factors

Consanguinity is believed to be a major risk factor.

Screening

Natural History, Complications, and Prognosis

The disease is typically progressive, leading to fulminant liver failure and death in childhood, in the absence of liver transplantation.

Hepatocellular carcinoma may develop in PFIC-2 at a very early age; even toddlers have been affected.

Patients may have fat malabsorption, leading to fat soluble vitamin deficiency, and complications, including osteopenia. [3]

Diagnosis

History and Symptoms

The onset of the disease is usually before age 2, but patients have been diagnosed with PFIC even into adolescence. Of the three entities, PFIC-3 usually presents earliest. Patients usually present in early childhood with cholestasis, jaundice, and failure to thrive. Intense pruritus is characteristic;[4] in patients who present in adolescence, it has been linked with suicide. Patients may have fat malabsorption, leading to fat soluble vitamin deficiency, and complications, including osteopenia. [5]

Physical Examination

Laboratory Findings

Biochemical markers include a normal GGT for PFIC-1 and -2, with a markedly elevated GGT for PFIC-3. Serum bile acid levels are grossly elevated. Serum cholesterol levels are typically not elevated, as is seen usually in cholestasis, as the pathology is due to a transporter as opposed to an anatomical problem with biliary cells.

Other Imaging Findings

Other Diagnostic Studies

Liver biopsy

Liver biopsies typically show evidence of cholestasis (including bile plugs and bile infarcts), duct hypoplasia, hepatocellular injury, and Zone 3 fibrosis. Giant cell change and other features of hepatocellular injury are more pronounced in PFIC-2 than in PFIC-1 or PFIC-3. End-stage disease in all forms of PFIC defined to date is characterized by bridging fibrosis with duct proliferation in peri-portal regions.[6]

Treatment

Medical Therapy

Initial treatment is supportive, with the use of agents to treat cholestasis and pruritus, including the following:

Patients should be supplemented with fat soluble vitamins, and occasionally medium-chain triglycerides in order to improve growth.

When liver synthetic dysfunction is significant, patients should be listed for transplantation. Family members should be tested for PFIC mutations, in order to determine risk of transmission.

Surgery

Prevention

See also

Support groups - pediatric

References

  1. Bull LN, van Eijk MJ, Pawlikowska L; et al. (1998). "A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis". Nat. Genet. 18 (3): 219–24. doi:10.1038/ng0398-219. PMID 9500542.
  2. Jacquemin E, De Vree JM, Cresteil D; et al. (2001). "The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood". Gastroenterology. 120 (6): 1448–58. PMID 11313315.
  3. "eMedicine - Progressive Familial Intrahepatic Cholestasis : Article by Karan M Emerick, MD". Retrieved 2007-07-21.
  4. Shneider BL (2004). "Progressive intrahepatic cholestasis: mechanisms, diagnosis and therapy". Pediatric transplantation. 8 (6): 609–12. doi:10.1111/j.1399-3046.2004.00240.x. PMID 15598335.
  5. "eMedicine - Progressive Familial Intrahepatic Cholestasis : Article by Karan M Emerick, MD". Retrieved 2007-07-21.
  6. Alonso EM, Snover DC, Montag A, Freese DK, Whitington PF (1994). "Histologic pathology of the liver in progressive familial intrahepatic cholestasis". J. Pediatr. Gastroenterol. Nutr. 18 (2): 128–33. PMID 8014759.


Template:WH Template:WS